Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat colorectal cancer: phase 3 trial launches

NCT ID NCT07525206

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 21 times

Summary

This Phase 3 study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in 700 adults with advanced colorectal cancer that has stopped responding to prior therapies. The goal is to see if the new combo shrinks tumors or helps people live longer. Participants will be randomly assigned to one of the two treatment groups and monitored for about 36 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
telisotuzumab adizutecan plus bevacizumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to other therapies.
What could go wrong
This is an early-stage Phase 3 trial, so the new drug may not prove more effective or safer than the current standard. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

  • AZ Maria Middelares /ID# 280141

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • AZ-Delta. /ID# 279329

    RECRUITING

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Algemeen Ziekenhuis klina /ID# 279331

    NOT_YET_RECRUITING

    Brasschaat, Antwerpen, 2930, Belgium

  • Astera Cancer Care /ID# 279532

    RECRUITING

    East Brunswick, New Jersey, 08816-4096, United States

  • Athens Medical Center - Psychikon Branch /ID# 279134

    RECRUITING

    Athens, Attica, 11525, Greece

  • CHA Bundang Medical Center /ID# 279589

    RECRUITING

    Seongnam, Gyeonggido, 13496, South Korea

  • Chi Mei Medical Center /ID# 279710

    RECRUITING

    Tainan, 71004, Taiwan

  • Compass Oncology - Rose Quarter /ID# 280127

    RECRUITING

    Portland, Oregon, 97227, United States

  • Dong-A University Medical Center /ID# 279610

    RECRUITING

    Busan, Busan Gwang Yeogsi, 49201, South Korea

  • E-Da Cancer Hospital /ID# 279745

    RECRUITING

    Kaohsiung City, 824, Taiwan

  • Gachon University Gil Medical Center /ID# 279592

    RECRUITING

    Incheon, Gyeonggido, 21565, South Korea

  • Grand Hopital de Charleroi - Les Viviers /ID# 279336

    RECRUITING

    Charleroi, Hainaut, 6280, Belgium

  • Hospital Clinico Universitario de Valencia /ID# 279645

    RECRUITING

    Valencia, 46010, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 279650

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Universitario 12 de Octubre /ID# 279659

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario La Paz /ID# 279664

    RECRUITING

    Madrid, 28046, Spain

  • Hospital de la Santa Creu i Sant Pau /ID# 279642

    RECRUITING

    Barcelona, 08041, Spain

  • Imelda Ziekenhuis /ID# 279333

    RECRUITING

    Bonheiden, Antwerpen, 2820, Belgium

  • Institut Jules Bordet /ID# 279406

    RECRUITING

    Anderlecht, Brussels Capital, 1070, Belgium

  • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 279702

    RECRUITING

    Porto, 4200-072, Portugal

  • Kobe City Medical Center General Hospital /ID# 280233

    RECRUITING

    Kobe, Hyōgo, 650-0047, Japan

  • National Cancer Center Hospital East /ID# 279917

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Hospital Organization Shikoku Cancer Center /ID# 280224

    RECRUITING

    Matsuyama, Ehime, 791-0280, Japan

  • Northwell Health Center for Advanced Medicine. /ID# 279590

    RECRUITING

    Lake Success, New York, 11042, United States

  • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare /ID# 279708

    RECRUITING

    New Taipei City, 235, Taiwan

  • Taipei Medical University Hospital /ID# 280607

    RECRUITING

    Taipei, Tainan, 110, Taiwan

  • Taipei Municipal Wan Fang Hospital /ID# 280285

    RECRUITING

    Taipei, 116, Taiwan

  • The Catholic University Of Korea St. Vincent's Hospital /ID# 279675

    RECRUITING

    Suwon, Gyeonggido, 16247, South Korea

  • Tri-Service General Hospital - Neihu Branch /ID# 279768

    RECRUITING

    Taipei, 114, Taiwan

  • Unidade Local de Saude de Almada-Seixal, EPE /ID# 279637

    RECRUITING

    Almada, Setúbal District, 2805-267, Portugal

  • Unidade Local de Saude de Loures-Odivelas /ID# 279636

    RECRUITING

    Loures, Lisbon District, 2674-514, Portugal

  • Unidade Local de Saude de Santa Maria /ID# 279624

    RECRUITING

    Lisbon, 1649-035, Portugal

  • Unidade Local de Saude do Alto Ave, EPE /ID# 279703

    RECRUITING

    Guimarães, Braga District, 4835-044, Portugal

  • Universitair Ziekenhuis Antwerpen /ID# 279334

    RECRUITING

    Edegem, Antwerpen, 2650, Belgium

  • University Of Washington-Fred Hutchinson Cancer Center - Seattle /ID# 281451

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.